Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
Ibrutinib modulates the immunosuppressive CLL microenvironment through STAT3-mediated suppression of regulatory B cell function and inhibition of the PD-1/PD-L1 pathway
Leukemia ( IF 12.8 ) Pub Date : , DOI: 10.1038/leu.2017.304 K Kondo , H Shaim , P A Thompson , J A Burger , M Keating , Z Estrov , D Harris , E Kim , A Ferrajoli , M Daher , R Basar , M Muftuoglu , N Imahashi , A Alsuliman , C Sobieski , E Gokdemir , W Wierda , N Jain , E Liu , E J Shpall , K Rezvani
Leukemia ( IF 12.8 ) Pub Date : , DOI: 10.1038/leu.2017.304 K Kondo , H Shaim , P A Thompson , J A Burger , M Keating , Z Estrov , D Harris , E Kim , A Ferrajoli , M Daher , R Basar , M Muftuoglu , N Imahashi , A Alsuliman , C Sobieski , E Gokdemir , W Wierda , N Jain , E Liu , E J Shpall , K Rezvani
Ibrutinib modulates the immunosuppressive CLL microenvironment through STAT3-mediated suppression of regulatory B cell function and inhibition of the PD-1/PD-L1 pathway
中文翻译：
依鲁替尼通过STAT3介导的调节性B细胞功能抑制和PD-1 / PD-L1途径抑制来调节免疫抑制性CLL微环境
依鲁替尼通过STAT3介导的调节性B细胞功能抑制和PD-1 / PD-L1途径抑制来调节免疫抑制性CLL微环境
更新日期：2017-10-11
Leukemia, Published online: 3 October 2017; doi:10.1038/leu.2017.304
中文翻译：
依鲁替尼通过STAT3介导的调节性B细胞功能抑制和PD-1 / PD-L1途径抑制来调节免疫抑制性CLL微环境
依鲁替尼通过STAT3介导的调节性B细胞功能抑制和PD-1 / PD-L1途径抑制来调节免疫抑制性CLL微环境
白血病，在线发布：2017年10月3日; doi：10.1038 / leu.2017.304
京公网安备 11010802027423号